Liver

Rheumatic Disease eJournal Club

Treatment of Rheumatoid Arthritis
With a Syk Kinase Inhibitor:
A Twelve-Week, Randomized, Placebo-Controlled Trial

Publication: Weinblatt M, et al. Arthritis Rheum. 2008;58:3309-3318.

Print this Content

 

Release Date: March 3, 2009
Renewal Date: March 3, 2010
Expiration Date: March 3, 2011

 

 

How to Obtain AMA PRA
Category 1 Credit™

  1. View the slides.
  2. Listen to the
    audio discussion.
  3. Login to your account.
  4. Complete the registration / evaluation form.
  5. Print your personalized
    CME certificate.

Technical Requirements

 

Estimated Time of Completion: 30 minutes

Description
To evaluate the safety and efficacy data from a randomized, placebo-controlled phase 2 clinical trial of a spleen tyrosine kinase (Syk) inhibitor in patients with active RA despite methotrexate therapy.

Objectives
On completion of this activity, participants should be able to:

  1. Outline the role of Syk in the immunopathogenesis of RA.
  2. Compare and contrast the effects of placebo and Syk inhibition on measures of disease activity.
  3. Describe the adverse events resulting from Syk inhibition.

Target Audience
This activity is directed to physicians, nurse practitioners, physician assistants, and other healthcare professionals interested in RA.

Accreditation
The Cleveland Clinic Foundation Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Cleveland Clinic Foundation Center for Continuing Education designates this educational activity for a maximum of .50 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

This activity may be submitted for American Osteopathic Association Continuing Medical Education credit in Category 2.

Activity Director

Leonard H. Calabrese, DO
Professor of Medicine
Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
Vice Chairman
Department of Rheumatic & Immunologic Diseases
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, Ohio

Faculty

Michael C. Weinblatt, MD
John R. and Eileen K. Riedman Professor of Medicine
Harvard Medical School
Division of Rheumatology, Immunology and Allergy
Brigham and Women’s Hospital
Boston, Massachusetts

Faculty Disclosure
In accordance with the Standards for Commercial Support issued by the Accreditation Council for Continuing Medical Education (ACCME), The Cleveland Clinic Foundation Center for Continuing Education requires resolution of all faculty conflicts of interest to ensure CME activities are free of commercial bias.

The following faculty has indicated that he may have a relationship, which in the context of his presentation(s), could be perceived as a potential conflict of interest:

Leonard Calabrese, DO
  Consulting: Abbott Laboratories; Elan, Genentech, Inc.; Roche Laboratories, Inc.
 
  Teaching and Speaking: Genentech, Inc.
 
Michael C. Weinblatt, MD
  Consulting: Abbott Laboratories; Amgen Inc.; Avidimer Therapeutics; AstraZeneca Pharmaceuticals LP; Biogen Idec; Bristol-Myers Squibb Company; CanFite BioPharma Ltd.; Centocor, Inc.; CombinatoRx; Crescendo Corp.; Eli Lilly and Company; EntreMed, Inc.; Genentech, Inc.; GlaxoSmithKline; Hollis-Eaton; Horizon Therapeutics; Idera Pharmaceuticals, Inc.; Johnson & Johnson; Medarex, Inc.; MedImmune Inc.; Merrimack Pharmaceuticals; Merck & Co., Inc.; Millennium Pharmaceuticals, Inc.; Novartis AG; Pfizer Inc.; Reata Pharmaceuticals, Inc.; Rigel Pharmaceuticals, Inc.; Roche Laboratories, Inc.; sanofi-aventis Group; Serona; UCB; VBL Technologies; VLST Corporation, Inc.; Wyeth Pharmaceuticals
 
  Teaching and Speaking: Abbott Laboratories; Amgen Inc.; Wyeth Pharmaceuticals
 
  Stock Options: CanFite BioPharma Ltd.; EntreMed, Inc.; Merrimack Pharmaceuticals; VBL Technologies
 
  Grant/Research Support: Amgen Inc.; Abbott Laboratories; Bristol-Myers Squibb Company; Crescendo Corp.; Genentech, Inc.; Millennium Pharmaceuticals, Inc./Biogen Idec.
 
  Medical Education: Editor of the Rheumatology Forum, an online physician forum with BIOCRITIQUE and funded by grants from Bristol-Myers Squibb Company; Genentech, Inc.; Amgen, Inc.; and Wyeth Pharmaceuticals; Co-editor of the International Journal of Advances in Rheumatology, an online journal with Remedica Medical Education and funded by a grant from Abbott Laboratories; Co-Director of the RA education program RAPID with Chatham Institute and funded by grants from Abbott Laboratories; Amgen, Inc.; Centocor, Inc.; and Wyeth Pharmaceuticals; Co-Director for case study in RA with Harvard Medical School and funded by a grant from TAP Pharmaceuticals
 
  Other: TEAR Study Data Safety Monitoring Board Member with University of Alabama and funded by grants from Amgen, Inc., Barr Pharmaceuticals, and Pfizer

The Cleveland Clinic Foundation Center for Continuing Education
acknowledges an educational grant for support of this activity from:

Roche Laboratories, Inc.

This CME activity was produced by The Cleveland Clinic Foundation
Center for Continuing Education and DIME .

CME Disclaimer